Newly developed retatrutide, a combined-action drug targeting equally GLP-1 and GIP receptors, is creating considerable excitement within the medical community. Early clinical studies have revealed significant reductions in overall mass and advancements in physiological markers for patients with excess weight . Scientists believe this ground-br… Read More